On April 1, 2020 the United States Food and Drug Association (“FDA”) announced that it was requesting drug manufacturers withdraw all prescription and over-the-counter (“OTC”) drugs containing ranitidine from the market immediately. This is the latest step in the FDA’s ongoing investigation into the cancer risks of ranitidine products such as the popular brand name heartburn drug Zantac.
Effective immediately, these products will not be available for new or existing prescriptions in the U.S., and the FDA is also recommending that consumers stop taking any ranitidine drugs that they currently have. Consumers that already have ranitidine products in their possession should dispose of them.
This action comes on the heels of new FDA testing and evaluation prompted by third-party laboratories that found carcinogen N-Nitrosodimethylamine (“NDMA”) in ranitidine drugs in amounts larger than are safe for human consumption.
You can read the full FDA statement here.
If you have been diagnosed with cancer after taking ranitidine products such as Zantac, Miller DellaFera PLC is standing by to help. You can get more information about the case on our Zantac Cancer Litigation page here, or you can reach out to our attorneys to discuss your claim:
- E-mail our attorneys
- Give us a call
- Or complete the form below.